Economics of Innovation
Optimal innovation balances willingness and ability to pay with the benefits of future R&D. Our wide-ranging programme aims to promote innovation in health care, increase our understanding of its value, and encourage R&D. New models of innovation should streamline development, reduce costs, and speed patient benefit.
Prices, Competition and Regulation in Pharmaceuticals: A Cross-National Comparison
1 June 2000
Most countries regulate manufacturer prices for pharmaceuticals, either directly (France, Italy) or indirectly through controls on reimbursement (Germany, Japan) or profits (the UK). It is widely…
Genomics, Healthcare and Public Policy
1 October 1999
This Conference on Genomics, Healthcare and Public Policy, organised by the Office of Health Economics in collaboration with the School of Public Policy, University College London,…
Risk and Return in the Pharmaceutical Industry
1 August 1999
This book has been built up from the papers delivered at the Office of Health Economics conference which took place at the Langham Hilton Hotel, London,…
Trade Mark Legislation and the Pharmaceutical Industry
1 May 1999
A trade mark is, in its most basic sense, a badge of identity. Its most essential characteristic is its capacity to distinguish one undertaking’s goods or…
Disease Management, the NHS and the Pharmaceutical Industry
1 March 1999
Forms of health care management exist that embody all the principles of disease management, but which are given a different label. In this report, we explore…
Updating the Cost of a New Chemical Entity
1 February 1999
The objective of this paper is to analyse the existing estimates of NCE costs and look at the subsequent changes in cost components and at the…
Competition through Innovation, Innovation through Competition
1 November 1998
Pharmaceutical companies report that in their dynamic, research and technology intensive industry, competitiveness is synonymous with innovativeness. That is, companies must invest in product research and…
Biotechnology and the Economics of Discovery in the Pharmaceutical Industry
1 October 1998
This paper examines the economic aspects of the forces driving the emergence of biotechnology firms, and the implications of this for the organisation of research and…
Regulating Prices Paid by the NHS for Medicines Supplied by the UK-Based Pharmaceutical Industry
1 October 1997
The aim of this paper is to review alternative methods of regulating the price of pharmaceuticals bought by the NHS from the perspective of the experience of the economic regulation of other industries in the UK, notably the privatised utilities.